Isoprenaline

Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)

Retrieved on: 
Thursday, December 7, 2023
Health, Neurology, General Health, Research, Pharmaceutical, Science, COMT, Medicine, Capsule, Sleep, Aggression, BIAL, Brain, Behavior, NYSE, Hormone, Senior, Food, Parkinson's disease, Eating, Movement, Gambling, Liver, PD, Delusion, Hallucination, Constipation, Sleep disorder, Patient, Multimedia, Dopamine, Dobutamine, Carbidopa, Behavior informatics, FDA, Isocarboxazid, Isoprenaline, Catecholamine, Vitamin, Partnership, Norepinephrine, Carbidopa/levodopa, Adrenaline, L-DOPA, Phenelzine, Mouth, Hearing, Physician, Neoplasm, Dyskinesia, Medication, Somnolence, Accident, Dizziness, Tranylcypromine, Weight loss, Psychosis, Pharmaceutical industry, Birth control, S.A, Amneal Pharmaceuticals, LD

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) and BIAL - Portela & Ca., S.A. (“BIAL”), today announced a licensing agreement where Amneal will have exclusive rights to market and distribute ONGENTYS® (opicapone) in the U.S. starting on December 18, 2023.

Key Points: 
  • Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) and BIAL - Portela & Ca., S.A. (“BIAL”), today announced a licensing agreement where Amneal will have exclusive rights to market and distribute ONGENTYS® (opicapone) in the U.S. starting on December 18, 2023.
  • Carbidopa/levodopa (CD/LD), which works to control the symptoms of PD, has been the gold-standard treatment for PD since the 1970s.
  • ONGENTYS® works by inhibiting the COMT enzyme – which breaks down LD – making more LD available to reach the brain, thereby reducing “Off” time.
  • The financial terms of the agreement were not disclosed, and any incremental expenses associated with this product are contemplated within Amneal’s guidance.

FluidForm Presents Data Demonstrating Performance of its Cardiac Drug Discovery Platform

Retrieved on: 
Tuesday, March 28, 2023
Heart, Human, BioRxiv, Engineering, 3D, Physiology, Disease, Cell, Merck & Co., Biomedical engineering, Biomedicine, Carnegie Mellon University, Isoprenaline, Biomedical Engineering Society, Drug discovery, Toxicology, Materials science, Merck, Pharmacology, CDDP, Pharmaceutical industry, MD

SUDBURY, Mass., March 28, 2023 /PRNewswire-PRWeb/ --FluidForm, a leader in manufacturing human tissue for drug discovery, announced the presentation of data from its Cardiac Drug Discovery Platform (CDDP) last Thursday at the Biomedical Engineering Society Advanced BioManufacturing meeting in Hyattsville, MD. In his keynote presentation, FluidForm's CTO, Professor Adam Feinberg, shared data that demonstrates the hallmarks of engineered human cardiac tissue, including highly aligned cells at true physiologic density, with reproducible calcium transients and fast conduction velocity. When subjected to the β-adrenergic receptor agonist isoproterenol, tissue showed native-like positive chronotropic and inotropic responses, a combination of responses that is not typically observed in 2D monolayer models or standard 3D engineered heart tissue approaches. The study, FRESH™ 3D bioprinted cardiac tissue, a bioengineered platform for in-vitro toxicology and pharmacology, was conducted by scientists at FluidForm and Merck & Co., and published to the preprint server bioRxiv.

Key Points: 
  • SUDBURY, Mass., March 28, 2023 /PRNewswire-PRWeb/ --FluidForm, a leader in manufacturing human tissue for drug discovery, announced the presentation of data from its Cardiac Drug Discovery Platform (CDDP) last Thursday at the Biomedical Engineering Society Advanced BioManufacturing meeting in Hyattsville, MD.
  • The study, FRESH™ 3D bioprinted cardiac tissue, a bioengineered platform for in-vitro toxicology and pharmacology , was conducted by scientists at FluidForm and Merck & Co., and published to the preprint server bioRxiv.
  • "Cardiac drug discovery has been a particular challenge for many years," said Feinberg, FluidForm's CTO and Professor in the Departments of Biomedical Engineering and Materials Science and Engineering at Carnegie Mellon University.
  • FluidForm's CDDP provides its pharmaceutical partners with data predictive of how a drug will affect cardiac tissue long before a drug is ever studied in humans.

Amring Pharmaceuticals Inc. Announces the Approval and Launch of Generic Isoproterenol Hydrochloride Injection USP

Retrieved on: 
Thursday, August 5, 2021
Biotechnology, FDA, Pharmaceutical, Health, Chief executive officer, Efficiency, Heart block, Cardiac arrest, Injury, Cardiogenic shock, Heart, Septic shock, Hypovolemia, Isoprenaline, Patient, Perfusion, Food and Drug Administration, AP, Biotechnology, Anesthesia, Bronchospasm, Medical device, Fine chemical, Amring Pharmaceuticals Inc., SEVER Life Sciences B.V., AMRING PHARMACEUTICALS INC., SEVER LIFE SCIENCES B.V.

Amring Pharmaceuticals Inc. (Amring), a niche generic and brand pharmaceutical company, announced today that it has received FDA approval for generic Isoproterenol Hydrochloride USP, (0.2 mg/mL) available as 1 mL or 5 mL Single-Dose Vials, (AP rated generic equivalent of Isuprel), and has immediately begun commercialization activity.

Key Points: 
  • Amring Pharmaceuticals Inc. (Amring), a niche generic and brand pharmaceutical company, announced today that it has received FDA approval for generic Isoproterenol Hydrochloride USP, (0.2 mg/mL) available as 1 mL or 5 mL Single-Dose Vials, (AP rated generic equivalent of Isuprel), and has immediately begun commercialization activity.
  • "We are pleased to add Isoproterenol Hydrochloride Injection USP to our generics portfolio, this product brings long term value to patients and customers in our target markets, stated Daniel Carbery, President and CEO of Amring.
  • We look forward to realizing the benefits of this, and other product launches and future business development activities in 2021.
  • Amring Pharmaceuticals is a privately held pharmaceutical company that provides niche generics and value-driven brands to the market.